Arcutis Biotherapeutics, Inc.
US ˙ NasdaqGS ˙ US03969K1088

SecurityARQT / Arcutis Biotherapeutics, Inc.
InstitutionStandard Life Aberdeen plc
Latest Disclosed Ownership645,066 shares
Latest Disclosed Value $ 15,197,755
Standard Life Aberdeen plc reports 10.00% increase in ownership of ARQT / Arcutis Biotherapeutics, Inc.

On April 29, 2026 - Standard Life Aberdeen plc filed a 13F-HR form disclosing ownership of 645,066 shares of Arcutis Biotherapeutics, Inc. (US:ARQT) valued at $15,197,755 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 16, 2026 disclosing 586,397 shares of Arcutis Biotherapeutics, Inc.. This represents a change in shares of 10.00% during the quarter. The current value of the position is $13,694,751 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-29 2026-03-31 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 645,066 58,669 10.00 15,198 -10.75 0.0133
2026-01-16 2025-12-31 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 586,397 -88,637 -13.13 17,029 33.83 0.0147
2025-11-07 2025-09-30 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 675,034 0 0.00 12,724 34.46 0.0201
2025-07-24 2025-06-30 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 675,034 87,494 14.89 9,464 2.98 0.0161
2025-05-13 2025-03-31 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 587,540 105,466 21.88 9,189 36.84 0.0179
2025-01-24 2024-12-31 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 482,074 0 0.00 6,715 49.79 0.0126
2024-10-25 2024-09-30 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 482,074 333,200 223.81 4,483 223.92 0.0082
2024-08-09 2024-06-30 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 148,874 0 0.00 1,385 -6.17 0.0027
2024-05-09 2024-03-31 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 148,874 0 0.00 1,475 207.29 0.0029
2024-01-31 2023-12-31 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 148,874 148,874 481 0.0010
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.